About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker CHRS · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 1, 2026Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carci…
NCT05359861 · Hepatocellular Carcinoma
Casdozokitug, Atezolizumab
CHRS
Coherus Oncology, Inc.
Phase 2Terminated30Jun 30, 2025Registry ↗
Aug 12, 2026Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643 · Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
CHS-114, toripalimab
CHRS
Coherus Oncology, Inc.
Phase 1Active, not recruiting87Sep 30, 2026Registry ↗
Jul 30, 2026A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent…
NCT06457503 · Nasopharyngeal Cancer Recurrent
Toripalimab, Cisplatin
CHRS
Coherus Oncology, Inc.
Phase 4Recruiting100Dec 2027Registry ↗
Jul 15, 2026A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unres…
NCT06679985 · Hepatocellular Carcinoma
Casdozokitug, Toripalimab
CHRS
Coherus Oncology, Inc.
Phase 2Active, not recruiting72Sep 2027Registry ↗
Jul 15, 2026A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Particip…
NCT06657144 · Metastatic Solid Tumor, Advanced Solid Tumor
CHS-114, Toripalimab
CHRS
Coherus Oncology, Inc.
Phase 1Recruiting154Jan 2028Registry ↗
Jul 15, 2026Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
NCT04374877 · Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma
CHS-388, Pembrolizumab
CHRS
Coherus Oncology, Inc.
Phase 1Completed145May 28, 2025Registry ↗
May 8, 2025Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Cast…
NCT05177770 · Metastatic Castration-resistant Prostate Cancer, Prostate C…
SRF617, etrumadenant
CHRS
Coherus Oncology, Inc.
Phase 2Terminated16Apr 5, 2023Registry ↗
May 1, 2025Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advance…
NCT05757492 · Advanced Solid Tumor, Non-Small Cell Lung Cancer
CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)
CHRS
Coherus Oncology, Inc.
Phase 1Terminated22Jul 31, 2024Registry ↗
Sep 19, 2024A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
NCT06389526 · Advanced or Metastatic Solid Tumors
CHS-1000, Toripalimab
CHRS
Coherus Oncology, Inc.
Phase 1Not yet recruiting48May 30, 2028Registry ↗
Jun 4, 2024Study of SRF617 in Patients With Advanced Solid Tumors
NCT04336098 · Advanced Solid Tumor
SRF617, Gemcitabine
CHRS
Coherus Oncology, Inc.
Phase 1Completed85Aug 25, 2023Registry ↗
Dec 23, 2020An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
NCT04662892 · Febrile Neutropenia, Non-myeloid Malignancy
Pegfilgrastim-Cbqv
CHRS
Coherus Oncology, Inc.
—Unknown200Nov 1, 2022Registry ↗
Apr 8, 2020Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
NCT02489227 · Plaque Psoriasis
CHS-1420, Adalimumab
CHRS
Coherus Oncology, Inc.
Phase 3Completed545May 6, 2016Registry ↗
Jun 28, 2019Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
NCT02134210 · Plaque Psoriasis
Etanercept, CHS-0214
CHRS
Coherus Oncology, Inc.
Phase 3Completed521Jul 27, 2015Registry ↗
Jun 26, 2019Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
NCT02115750 · Rheumatoid Arthritis
Etanercept, CHS-0214
CHRS
Coherus Oncology, Inc.
Phase 3Completed647Oct 2015Registry ↗
Dec 27, 2018A Long Term Safety Extension Study (CHS-0214-05)
NCT02486939 · Rheumatoid Arthritis, Plaque Psoriasis
CHS-0214
CHRS
Coherus Oncology, Inc.
Phase 3Completed359Sep 2017Registry ↗
Aug 1, 2016Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta
NCT02650973 · Healthy
CHS-1701, Pegfilgrastim
CHRS
Coherus Oncology, Inc.
Phase 1Completed122Jun 2016Registry ↗
Jan 7, 2016Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Sub…
NCT02418104 · Immunity, Humoral
CHS-1701, Pegfilgrastim (Neulasta)
CHRS
Coherus Oncology, Inc.
Phase 1Completed303Dec 2015Registry ↗
Aug 13, 2015Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgras…
NCT02385851 · Bioequivalence
CHS-1701, Pegfilgrastim
CHRS
Coherus Oncology, Inc.
Phase 1Completed116Jul 2015Registry ↗

18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:20 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances